Aarti Drugs Ltd
AARTIDRUGS
Company Profile
Business description
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs), pharma intermediaries, specialty chemicals, and formulations in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm caters to both domestic and international markets and derives a majority of its revenue from its business in India.
Contact
Road No. 29, Plot Number 109-D
Mahendra Industrial Estate, Ground Floor
Sion (East)
MumbaiMH400022
INDT: +91 2224019025
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2025
Employees
2,766
Stocks News & Analysis
stocks
The ASX healthcare player soaring to all-time highs
The steep market reaction comes after a recent announcement by the ACCC
stocks
Ask the analyst: How long is WiseTech's growth runway?
Roy Van Keulen answers my question on how big a growth opportunity remains for the ASX's biggest technology company.
video
Why the ASX's most overlooked world champion is no dinosaur
Brambles is the undisputed king of pallet pooling. Esther Holloway joined me to talk about its moat, growth prospects and risk of disruption.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,416.60 | 57.70 | -0.68% |
| CAC 40 | 7,541.36 | 63.58 | 0.85% |
| DAX 40 | 19,120.93 | 105.52 | 0.55% |
| Dow JONES (US) | 42,352.75 | 341.16 | 0.81% |
| FTSE 100 | 8,280.63 | 1.89 | -0.02% |
| HKSE | 22,736.87 | 623.36 | 2.82% |
| NASDAQ | 18,137.85 | 219.37 | 1.22% |
| Nikkei 225 | 38,635.62 | 83.56 | 0.22% |
| NZX 50 Index | 12,619.94 | 47.28 | 0.38% |
| S&P 500 | 5,751.07 | 51.13 | 0.90% |
| S&P/ASX 200 | 8,150.00 | 55.20 | -0.67% |
| SSE Composite Index | 3,336.50 | 248.97 | 8.06% |